Repeat Therapeutics
Repeat Therapeutics is a biotechnology company developing first-in-human therapies for amyotrophic lateral sclerosis (ALS) by targeting the underlying biology of repeat expansion diseases. The company is advancing a discovery-stage pipeline toward clinical development, with a scientific foundation built on RNA research and a focus on translational medicine. Its programs are designed to address the root genetic drivers of neurodegeneration rather than only managing symptoms.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Neurodegenerative diseases such as ALS remain devastating conditions with limited treatment options, and the underlying genetic mechanisms, including repeat expansion diseases, are not adequately addressed by current therapies. Patients with these progressive conditions face a significant unmet need for disease-modifying treatments that target the root cause of their illness.
Solution
Repeat Therapeutics is charting a science-driven path anchored in the biology of repeat expansion diseases to deliver first-in-class therapies for patients in need. The company is developing first-in-human therapies for ALS, leveraging insights into repeat expansion biology to create novel treatment approaches. The company is advancing its pipeline from discovery toward clinical development, with a focus on translational medicine and early clinical execution. The scientific foundation is built on deep expertise in neuroscience and drug development, positioning the company to address the underlying drivers of neurodegeneration.
Target Audience
Primary stakeholders are patients with neurodegenerative diseases, particularly those with ALS, and the clinical researchers and healthcare providers seeking new therapeutic options. The company also serves the broader life sciences ecosystem through its clinical development partnerships.
Features
- Focus on repeat expansion disease biology as the core therapeutic target
- Pipeline anchored in first-in-human therapies specifically for ALS
- Early-stage clinical development with leadership in translational medicine
- Commitment to patient-centered therapy development grounded in rigorous science
- Integration of clinical research operations with GCP-ICH compliance and data integrity standards